Antiretroviral therapy for the prevention of HIV-1 transmission

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 830-839

  Cohen, M S ^a   Chen, Y Q ^a   McCauley, M ^a   Gamble, T ^a   Hosseinipour, M C ^a   Kumarasamy, N ^a   Hakim, J G ^a   Kumwenda, J ^a   Grinsztejn, B ^a   Pilotto, J H S ^a   Godbole, S V ^a   Chariyalertsak, S ^a   Santos, B R ^a   Mayer, K H ^a   Hoffman, I F ^a   Eshleman, S H ^a   Piwowar Manning, E ^a   Cottle, L ^a   Zhang, X C ^a   Makhema, J ^a   Mills, L A ^a   Panchia, R ^a   Faesen, S ^a   Eron, J ^a   Gallant, J ^a   Havlir, D ^a   Swindells, S ^a   Elharrar, V ^a   Burns, D ^a   Taha, T E ^a   Nielsen Saines, K ^a   Celentano, D D ^a   Essex, M ^a   Hudelson, S E ^a   Redd, A D ^a   Fleming, T R ^a   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CD4+ T LYMPHOCYTE; CONDOM USE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION RISK; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEXUALITY; VIRUS TRANSMISSION; YOUNG ADULT; CLINICAL TRIAL; DISEASE TRANSMISSION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MULTICENTER STUDY; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; RISK; TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK; SEXUAL PARTNERS; YOUNG ADULT;

EID: 84985991364     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1600693     Document Type: Conference Paper

References (29)

1. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-9.
2. People living with HIV. UNAIDS. 2014 (http://aidsinfo .unaids .org/ #).
3. Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2013; 4: CD009153.
4. Muessig KE, Cohen MS. Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep 2014; 11: 434-46.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
6. Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: An ethical odyssey. Clin Trials 2012; 9: 340-7.
7. Chen YQ, Masse B, Wang L, et al. Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. Contemp Clin Trials 2012; 33: 1280-6.
8. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14: 281-90.
9. Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis 2011; 204: 1918-26.
10. Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: Evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS ONE 2013; 8(9): E71557.
11. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: Current and future implementation challenges. Clin Infect Dis 2016; 62: 1043-8.
12. Stürmer M, Doerr HW, Berger A, Gute P. Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? Antivir Ther 2008; 13: 729-32.
13. Vernazza PL, Hirschel B. HIV transmission hunting - the chase for low risk events. Antivir Ther 2008; 13: 641-2.
14. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 2013; 382: 1515-24.
15. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: World Health Organization, 2013.
16. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373: 808-22.
17. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368: 218-30.
18. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
19. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-39.
20. El-Sadr WM, Serwadda DM, Sista N, Cohen MS. HIV prevention: Great achievements, more challenges ahead. J Acquir Immune Defic Syndr 2013; 63: Suppl 2: S115-6.
21. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization, September 2015 (http://apps .who .int/ iris/ bitstream/ 10665/ 186275/ 1/ 9789241509565-eng .pdf).
22. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: Recommendations for a public health approach. Geneva: World Health Organization, 2012.
23. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med 2011; 8(11): E1001123.
24. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-9.
25. Rodger A, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016 July 12 (Epub ahead of print).
26. Boily MC, Mâsse B, Alsallaq R, et al. HIV treatment as prevention: Considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 2012; 9(7): E1001250.
27. Cori A, Ayles H, Beyers N, et al. HPTN 071 (PopART): A cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: Mathematical model. PLoS ONE 2014; 9(1): E84511.
28. Hayes R, Ayles H, Beyers N, et al. HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials 2014; 15: 57.
29. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2014